financetom
Business
financetom
/
Business
/
Wireless tech firm Ondas' Q3 revenue beats on unmanned platforms demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wireless tech firm Ondas' Q3 revenue beats on unmanned platforms demand
Nov 13, 2025 5:27 AM

Overview

* Ondas Q3 2025 revenue grows 6-fold yr/yr to $10.1 mln, beating analyst expectations

* Company raises 2025 revenue target to at least $36 mln, sets 2026 target at $110 mln

* Ondas ( ONDS ) strengthens position with acquisitions of Sentrycs and Apeiro Motion

Outlook

* Ondas ( ONDS ) raises 2025 revenue target to at least $36 mln

* Company sets preliminary 2026 revenue target at $110 mln

* Company expects continued strong growth into 2026

Result Drivers

* DEMAND FOR UNMANNED PLATFORMS - Ondas ( ONDS ) attributes record Q3 revenue growth to strong demand for its unmanned platforms, including Iron Drone Raider and Optimus System

* STRATEGIC ACQUISITIONS - Acquisitions of Sentrycs and Apeiro Motion expected to enhance counter-UAS and ground robotics capabilities

* DOT16 PLATFORM ADOPTION - Multiple railroads adopting Ondas Networks' dot16 platform for network modernization

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $10.10 $7.04

Revenue mln mln (7

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the communications & networking peer group is "buy"

* Wall Street's median 12-month price target for Ondas Holdings Inc ( ONDS ) is $9.50, about 42% above its November 12 closing price of $5.51

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dynavax Technologies Investor Deep Track Capital Nominates 4 Independent Directors
Dynavax Technologies Investor Deep Track Capital Nominates 4 Independent Directors
Feb 19, 2025
10:51 AM EST, 02/19/2025 (MT Newswires) -- Dynavax Technologies' ( DVAX ) shareholder Deep Track Capital nominated four independent directors to the biopharmaceutical company's board to focus on key hepatitis B vaccine Heplisav and shift away from acquisitions. Focusing on Heplisav could result in nearly $2 billion of cash being returned to shareholders by the end of 2030, Deep Track...
Kartoon Studios Launches Kartoon Channel! on Connected Samsung TVs in US, Canada
Kartoon Studios Launches Kartoon Channel! on Connected Samsung TVs in US, Canada
Feb 19, 2025
10:50 AM EST, 02/19/2025 (MT Newswires) -- Kartoon Studios ( TOON ) said Wednesday it has launched Kartoon Channel! throughout the US and Canada on connected Samsung TVs. Financial terms were not disclosed. Kartoon Studios' ( TOON ) stock rose 1.5% in recent Wednesday trading. Price: 0.65, Change: +0.01, Percent Change: +1.70 ...
Update: Novo Nordisk Seeking $830 Million From Singapore Firm Over Alleged Fraud
Update: Novo Nordisk Seeking $830 Million From Singapore Firm Over Alleged Fraud
Feb 19, 2025
10:51 AM EST, 02/19/2025 (MT Newswires) -- (Updates with statement from Novo Nordisk ( NVO ) in the fifth paragraph.) Novo Nordisk ( NVO ) is seeking up to $830 million in damages from KBP Biosciences, alleging the Singapore-based firm engaged in fraud during the 2023 sale of ocedurenone, a drug that supposedly treated hypertension, according to a Feb. 14...
X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries
X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries
Feb 19, 2025
10:53 AM EST, 02/19/2025 (MT Newswires) -- X4 Pharmaceuticals ( XFOR ) and Taiba Rare said Wednesday they have agreed to distribute and commercialize Xolremdi, or mavorixafor, an oral treatment for WHIM syndrome, which stands for warts, hypogammaglobulinemia, infections, and myelokathexis. The agreement covers Saudi Arabia, the United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt. WHIM syndrome is a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved